The revenue of the company grew by 36% YoY to INR 10,785 mn in line with our estimates of INR 10706 mn. The revenue growth was led by higher demand from value added products under speciality segment (+35% YoY) as well as pharmaceuticals segment (+41 YoY). EBITDA for the quarter stood at INR 1879 mn (+36% YoY; 4% QoQ). Operational performance was impacted by INR 289 mn on account of...